

March 15, 2011

**VIA EDGAR**

Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549

**Re: Nile Therapeutics, Inc. (the "Company")**

Dear Sir/Madam:

As counsel for the Company and on its behalf, enclosed herewith is the Company's Preliminary Proxy Statement on Schedule 14A relating to the Company's 2011 Annual Meeting of Stockholders.

Please contact the undersigned at (612) 492-7369 if you have any questions or comments with respect to the Preliminary Proxy Statement.

Sincerely,

*/s/ Christopher J. Melsha*

Christopher J. Melsha  
*Attorney*

**Direct Dial:** 612.492.7369

**Email:** cmelsha@fredlaw.com

cc: Mr. Daron Evans  
Chief Financial Officer  
Nile Therapeutics, Inc.

Attorneys & Advisors  
main 612.492.7000  
fax 612.492.7077  
www.fredlaw.com

Fredrikson & Byron, P.A.  
200 South Sixth Street, Suite 4000  
Minneapolis, Minnesota  
55402-1425

MEMBER OF THE WORLD SERVICES GROUP  
*A Worldwide Network of Professional Service Providers*

OFFICES  
Minneapolis / Bismarck / Des Moines / London / Monterrey, Mexico / Shanghai